Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
SPEX's Cash to Debt is ranked higher than
98% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.05 vs. SPEX: No Debt )
SPEX' s 10-Year Cash to Debt Range
Min: 0.14   Max: No Debt
Current: No Debt

Equity to Asset 0.90
SPEX's Equity to Asset is ranked higher than
94% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. SPEX: 0.90 )
SPEX' s 10-Year Equity to Asset Range
Min: 0.13   Max: 0.9
Current: 0.9

0.13
0.9
Interest Coverage No Debt
SPEX's Interest Coverage is ranked higher than
88% of the 102 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 127.94 vs. SPEX: No Debt )
SPEX' s 10-Year Interest Coverage Range
Min: 2.5   Max: 9999.99
Current: No Debt

2.5
9999.99
F-Score: 4
Z-Score: -0.74
M-Score: 33.74
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -118160.71
SPEX's Operating margin (%) is ranked lower than
59% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. SPEX: -118160.71 )
SPEX' s 10-Year Operating margin (%) Range
Min: -56840.74   Max: 3.65
Current: -118160.71

-56840.74
3.65
Net-margin (%) -117828.57
SPEX's Net-margin (%) is ranked lower than
59% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.29 vs. SPEX: -117828.57 )
SPEX' s 10-Year Net-margin (%) Range
Min: -66537.04   Max: 50185.71
Current: -117828.57

-66537.04
50185.71
ROE (%) -98.05
SPEX's ROE (%) is ranked lower than
52% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.42 vs. SPEX: -98.05 )
SPEX' s 10-Year ROE (%) Range
Min: -165.82   Max: 31.32
Current: -98.05

-165.82
31.32
ROA (%) -74.99
SPEX's ROA (%) is ranked lower than
53% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.28 vs. SPEX: -74.99 )
SPEX' s 10-Year ROA (%) Range
Min: -90.1   Max: 22.15
Current: -74.99

-90.1
22.15
ROC (Joel Greenblatt) (%) -1804636.36
SPEX's ROC (Joel Greenblatt) (%) is ranked lower than
59% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.50 vs. SPEX: -1804636.36 )
SPEX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -127891.67   Max: 31.25
Current: -1804636.36

-127891.67
31.25
Revenue Growth (%) -89.20
SPEX's Revenue Growth (%) is ranked lower than
51% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. SPEX: -89.20 )
SPEX' s 10-Year Revenue Growth (%) Range
Min: -100   Max: 468.4
Current: -89.2

-100
468.4
EBITDA Growth (%) -49.40
SPEX's EBITDA Growth (%) is ranked higher than
52% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. SPEX: -49.40 )
SPEX' s 10-Year EBITDA Growth (%) Range
Min: -53.4   Max: 153.3
Current: -49.4

-53.4
153.3
EPS Growth (%) -45.80
SPEX's EPS Growth (%) is ranked higher than
52% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. SPEX: -45.80 )
SPEX' s 10-Year EPS Growth (%) Range
Min: -56.1   Max: 131.7
Current: -45.8

-56.1
131.7
» SPEX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

SPEX Guru Trades in

SPEX Guru Trades in

Q2 2012

SPEX Guru Trades in Q2 2012

Jim Simons 87,176 sh (New)
» More
Q3 2012

SPEX Guru Trades in Q3 2012

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SPEX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.40
SPEX's P/B is ranked higher than
99% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.20 vs. SPEX: 0.40 )
SPEX' s 10-Year P/B Range
Min: 0.07   Max: 70.16
Current: 0.4

0.07
70.16
EV-to-EBIT 0.05
SPEX's EV-to-EBIT is ranked higher than
99% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 168.09 vs. SPEX: 0.05 )
SPEX' s 10-Year EV-to-EBIT Range
Min: 29.1   Max: 716.5
Current: 0.05

29.1
716.5
Current Ratio 7.84
SPEX's Current Ratio is ranked higher than
92% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. SPEX: 7.84 )
SPEX' s 10-Year Current Ratio Range
Min: 1   Max: 14.77
Current: 7.84

1
14.77
Quick Ratio 7.84
SPEX's Quick Ratio is ranked higher than
92% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.29 vs. SPEX: 7.84 )
SPEX' s 10-Year Quick Ratio Range
Min: 1   Max: 14.77
Current: 7.84

1
14.77

Valuation & Return

vs
industry
vs
history
Price/Net Cash 92.00
SPEX's Price/Net Cash is ranked higher than
78% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. SPEX: 92.00 )
SPEX' s 10-Year Price/Net Cash Range
Min: 0.68   Max: 236.05
Current: 92

0.68
236.05
Price/Net Current Asset Value 92.00
SPEX's Price/Net Current Asset Value is ranked higher than
73% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. SPEX: 92.00 )
SPEX' s 10-Year Price/Net Current Asset Value Range
Min: 0.66   Max: 326.67
Current: 92

0.66
326.67
Price/Tangible Book 92.00
SPEX's Price/Tangible Book is ranked higher than
56% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.22 vs. SPEX: 92.00 )
SPEX' s 10-Year Price/Tangible Book Range
Min: 0.62   Max: 182
Current: 92

0.62
182
Price/Median PS Value 8.40
SPEX's Price/Median PS Value is ranked lower than
53% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.41 vs. SPEX: 8.40 )
SPEX' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 731.25
Current: 8.4

0.12
731.25
Earnings Yield (Greenblatt) 2065.20
SPEX's Earnings Yield (Greenblatt) is ranked higher than
98% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.00 vs. SPEX: 2065.20 )
SPEX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 2087.9
Current: 2065.2

0.1
2087.9
Forward Rate of Return (Yacktman) -8408.53
SPEX's Forward Rate of Return (Yacktman) is ranked lower than
55% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.98 vs. SPEX: -8408.53 )
SPEX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -3.3   Max: -1.4
Current: -8408.53

-3.3
-1.4

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:BP2P.Germany
Spherix, Inc., is a Delaware corporation organized in 1967. The Company is a scientific research company. It has two principal segments Biospherics, biotechnology research and development business; and Health Sciences, a technical and regulatory consulting business. The Company provides management, strategic guidance, business development, marketing and other services to its subsidiaries. The Company do not own or operate its manufacturing facilities, and have purchased SPX106 and D-tagatose from toll manufacturers who also produce other compounds. Biospherics and the University of Kentucky Research Foundation (UKRF) have entered into a License Agreement pursuant to which UKRF has granted Biospherics an exclusive license to commercialize certain compounds including SPX106. Competitors of Biospherics are numerous and include, among others, major pharmaceutical, chemical, consumer, and biotechnology companies; specialized firms; universities and other research institutions.
» More Articles for SPEX

Headlines

Articles On GuruFocus.com
comment on SPEX Dec 02 2012 
Spherix Inc. Reports Operating Results (10-Q) Aug 13 2010 
Spherix Stockholders Authorize Potential Reverse Stock Split Dec 13 2008 

More From Other Websites
6:06 am Spherix notified by USPTO of new standard essential patent issued to co; provides update on... Sep 22 2014
Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued... Sep 22 2014
United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix Sep 02 2014
First Trial of Nortel Patents Since Bankruptcy Scheduled Against Verizon for First Quarter of 2015 Aug 25 2014
SPHERIX INC Financials Aug 22 2014
SPHERIX INC Files SEC form 10-Q, Quarterly Report Aug 13 2014
Patent Monetization Strategy Now Includes Nine Litigation Programs as Spherix Continues to Identify... Jul 29 2014
Spherix Schedules Shareholder Update Call Jul 24 2014
SPHERIX INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 10 2014
SPHERIX INC Files SEC form 8-K, Financial Statements and Exhibits Jun 20 2014
Spherix CEO to Speak at the IP Business Congress Global 2014 Conference Jun 19 2014
Why Spherix (SPEX) Stock Is Up Today Jun 17 2014
SPHERIX INC Files SEC form 8-K, Financial Statements and Exhibits Jun 17 2014
Spherix Set to Join Russell Microcap Index Jun 17 2014
SPHERIX INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Jun 13 2014
Spherix Appoints Jeff Ballabon to Board of Directors Jun 13 2014
SPHERIX INC Files SEC form 8-K, Financial Statements and Exhibits Jun 12 2014
Spherix begins litigation against Verizon for patent infringement Jun 12 2014
Spherix Commences Litigation Against Verizon for Patent Infringement Jun 12 2014
SPHERIX INC Files SEC form 8-K, Financial Statements and Exhibits Jun 11 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK